There is growing evidence that people with endometriosis are utilising cannabis, whether legally or illicitly procured, for management of pain and associated symptoms. As such, concerns over cannabis use as a medicine are foremost in clinicians' minds, particularly potential adverse effects. This study, a sub-set of a larger (n = 889) international survey investigating the self-reported effectiveness, safety and pharmaceutical de-prescribing trends of cannabis use in the endometriosis population, showed that 32% experienced side-effects associated with cannabis use, similar to published literature. However, some of these reported adverse effects have potential clinical utility and may require a more nuanced interpretation.